Computational Approaches for Supporting Combination Therapy in the Post-Aducanumab Era in Alzheimer's Disease
{{output}}
With the approval of aducanumab on the "Accelerated Approval Pathway" and the recognition of amyloid load as a surrogate marker, new successful therapeutic approaches will be driven by combination therapy as was the case in oncology after the launch of immune ... ...
